Earnings call transcript Q1 2023

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day and thank you for standing by. Welcome to the G1 Therapeutics First Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to hand over the conference to your speaker today, Will Roberts in Communications. Will, please go ahead.

Will Roberts

Mark. you, Thank and discuss everyone business the conference GX Good first welcome quarter to our and XXXX call morning, to financial update. results this found release results gXtherapeutics.com. of press these morning website, issued and The our corporate can a in on be News section was financial

the on in morning this our and the commercial progress regimen of clinical incidence period approved team who cancer. and of commercially small with XXXX, a decrease business will in programs On quarter a provide including available that COSELA, cell chemotherapy-induced the overview which patients of call, to first administered platinum/etoposide-containing is an update myelosuppression regimen for lung to prior or topotecan-containing our extensive-stage

mentioned, follow Mark As Q&A session a will remarks. the prepared

want forward-looking cause that remind webcast today as statements. the these from those to today’s and XXXX. expressed Act of meaning judgment involve I statements uncertainty to the Securities statements risk that contains or could Litigation by Private Reform implied of actual in materially may Such results of you we differ Before management’s within represent begin, and

more Securities For which of Exchange risk on website. corporate available refer uncertainties, statements on May our Any today, are XXXX. or the our and from SEC Commission, X, with filings forward-looking information to our as please represent such the and views

Chief John our Chief Perry, Joining Raj me Umstead, on the Officer. Malik, Officer, call Bailey, Chief Commercial Officer, our and Chief today Officer, Andrew are Executive Jack our Medical Financial

over Jack. And I with Jack? the that, turn to will call

Jack Bailey

thank joining today. you us for on Will. call Thanks morning, everyone the and Good

team March accelerate and of months. XX% we the the April vial XXXX one the the fourth quarter. in volume platform month-to-date our higher in rate saw quarter building The deeply to QX was quarter, organizations and well of over our over grew that we hear than COSELA was adopting growth of in As the Sales was from we saw you on a prior goal. will momentarily, highest XX% by is quarter our prior the XXXX. goal executed Andrew highest as volume by customer growing accelerated growth which also meaningfully volume of first

to continued and sales efforts. have We our learn evolve

net results, activities community are In right combination the the the these achieving of confidence first the improved settings. we our today. to million penetration right primarily guidance XXXX, reiterating XXXX, successful which $XX of in and to reinforcing quarter of in drug in lead accounts, sales directed increased are commercial with sales positive to and We $XX our in of identifying million execution experiences initiatives

as Now, particular the are this and near-term clinical two interim first cancer. readouts X regarding of Xs Raj in from with analysis in executing are ongoing our is on the Phase pipeline, those clinical the studies to XXXX. Phase presented and data data our we later Phase quarter X will TNBC Updated triple-negative breast Phase OF in trials discuss, X quarter the expected for now being occur our

expenses. in our last manner our is that mentioned of on call, and we as our mindful business cash conducting And are a

to goal diluted end, further even our This into these balance of to has a further extending runway this monetizing extend by readouts, runway our us we allowed now data $XX transaction milestones that in to brings in $XX Simcere. clinical and beyond our us from through all that This million manner the our royalties up readouts. our total. sheet we With future each million that and XXXX cash is of strengthened proactively morning and of shareholders non-equity cash have announced all to

the rest to the the of rights retain As a reminder, throughout world. we trilaciclib

data reserves. will will first order. for since first the will the addition and readouts. of cash our quarter provide you of guidance our be efforts cash start expense John remind and of back XXXX. revenue, And in to and these cover discuss the Raj I financial some upcoming comments. finally, Then concluding take will results the quarter of for our the the commercial we Andrew Now, will recent timing reiterate

the With turn that, call I over now to will Andrew.

Andrew Perry

am Thank sales an you, and to in be our Jack. we commercial with to execution recent progress over the I glad first our today quarter on you made update XXXX months. provide performance have

underlying broader deeply factors was some in on this platform customer the we quarter organizations. in today. adopting I QX the performance We will saw the building in by of discuss quarter XXXX the goal accelerate of fourth goal of first growth more our volume Our delivered to a and

has net sales with the with XXX%, since with growth XX% COSELA, This last of growth year. period compared Volume representing the was QX. XXXX of demonstrating ended volume been results, QX sales quarter with first our Beginning compared in we with $XX.X was vial our to quarter strongest of which March, growth All our and in growth ability in month experienced the in grew continued growth quarter vial per in territories generate day Average our our month quarter. being growth the volumes grew of three two-thirds launch-to-date. of the strongest each quarter-over-quarter regions year-over-year. double-digit million highest

new quarter, with either the have accounts, complete giving XX a total new the have is three accounts of is which ordering COSELA month on added organizations launch I from organizations of regimen XX and parent new organizations who XX the QX, over which existing In top expansive-stage and for XX of roughly we set and top XXX order quarterly in our from to in record on new best accounts QX, to-date. of stated cell was In affiliated to-date. top ordered broadest our quarter our of therapy. was total with of fourth new the larger March Many customers added. orders, first are XXX, in small launch in previously XXX which XXX lung had these growth market, brought XXXX. board highly reliant similar chemotherapy we their gaining new we for accounts drop-off patients accounts on As to cancer compensate patients or

Our high the customers XX% rate over remained reorder of within reordered and ordering quarter.

deep Going more customers top from new consistent customers forward important focus, ordering growth. large and for a sustained although is a XXX remain

to [indiscernible] XX per similar ordered ordered our regard adoption, and in of customers what vials we volume quarter In in in to in With top had XX five total organizations more period, QX, is XX% QX, XXX than QX. QX. which which the saw we

change to some was began organizations, top there the five some Although in more which composed the adopt deeply. as

care working engaged XX% was and of a for QX placement XXXX, default those compared includes volumes our new for organizations, who best COSELA a roughly utilization of the Xx in an focus place in contract contracted our in business customers where volume deeply in have to end in have is active which those elected of based COSELA EMR. QX, increased our agreement XX% customers of customers of their QX, simply who the we agreements, potential see with agreements Also left oncology By Our also of In more their to with position quarter. roughly several during who community deeper volume understand the with we optimal customers and COSELA who option. customers as demonstrate standard among adoption.

community and share use. and academic market, which grow first of not we Our our continues of and range fully estimate in volume of the come XX% centers. volume our quarter our saw the to was in patient volume the XX% for We clinics hospitals in X% X% assessments XX% program. of quarter through supply patient through commercial represents majority the with available, in COSELA line claims XX% QX of although estimate share patients data to are the from in provided

mix reimbursement majority covered remained has strong payer with Our by and Medicare stable the remained third-party

has been of one Moving highest into QX volume XXXX, April months. also our

duration chemotherapy volumes and small to the month-to-month limited always, as cell cancer. of vary Although due can lung

to strategic over seeing benefits large and focus community oncology continues last the execution quarters. we made customers shifts Our two the we on of the are have

will our to for model commercial COSELA. achieve We to evolve our ambitions as continue necessary

that, With will turn over to I call the Raj.

Raj Malik

data provide Updated coming quarters our Breast results the with next good a the data readouts presentation sacituzumab on over ADC to compared during poster clinically on trial first from exciting for sacituzumab on patients expected ASCENT data showed the the target to reduce Andrew combination May data events early been an important follow These from multiple Thanks, safety I and of that accepted promising single will meaningful the initial Cancer XX myeloprotection year. from and trilaciclib next effect have the update few the and the morning. adverse the of ESMO results XX. agent Conference rates trial.

trial trial results, survival presentation in further discuss moment. action for a from the Similarly, the on also first in been endpoints, efficacy tumor which The June results we mechanism important have data the topic expect I initial will status, quarter meeting most PD-LX include be including neoadjuvant to outcome from presentation updated our This of XXXX. of accepted TMBC will at will a overall ASCO X. reach this in by

presented alterations monotherapy data data T-reg to The showed the demonstrating last towards immunomodulatory of tumor will a Initial microenvironment include tumor effects of and signatures year trilaciclib following positive including with potential tumor status. complete the trilaciclib. analyses T-cell include related the dose increase PD-LX results, single in and tumor trilaciclib. an ratio in single CDX pathological favorable trend correlations pathological the response gene at of T-cell outcome baseline dose those but to response, Evaluating of following with also changes complete molecular immune memory, related by ASCO

results, efficacy in progression-free and this including safety X additional PRESERVE cancer provide to survival year. preliminary the bladder expect we from in middle of Next, results

XXXX. important look reach then quarter of in overall survival expect the to we which the first will to We forward endpoints,

overall following the that of the trial XXXX. pivotal Finally, quarter events, estimate now the survival evaluation interim and blinded a recent first analysis of occur we TNBC or

statistically trial in Phase As and patients that X.X X ratios foundational placebo, trilaciclib our on is arms significant of both compared trial for from based X.XX overall respectively. this a to enrolled showed survival data the but a reminder, hazard advantage

trial the rule the terminate and does meets will the will top it analysis. results. trial the line final If If GX to not, interim report it the analysis-stopping continue will

the Phase survival we TNBC free including Phase coming on endpoints. appears is keep including measures effect As have with rate and over namely other mind it’s like that greatest at to have endpoints. to a trial, what overall from inhibitors trilaciclib rather which Like these the as efficacy survival, X in longer consistent months, we greatest prior learned term studies effect survival. important the approach than data, as the Xs such progression This earlier checkpoint well, immunotherapies response have

that immune due surveillance of and generation and long-term trilaciclib Our as to this T-cells. increased certain memory data-to-date a be suggests could

potential of Additionally, long to the different see it take to how of efficacy, status may PD-LX tumors these any trilaciclib across measures affect that works likely benefit. including is how

survival. patients numerical metrics, microenvironment, we earlier PD-LX tumor in For inflamed immune including a an usually free efficacy positive and observed overall response have in with example, tumors, progression which improvement

curves continued Meier for Kaplan overall XX.X time. chemotherapy ratio This median XX.X patients a led of alone, survival the and survival separated improve Additionally, to compared receiving for receiving a with X.XX. early trilaciclib overall months over of hazard to months patients to

On improvement observe a tumor PD-LX other tend or in or to microenvironments, did immune we the not response excluded immune hand, negative tumors, with which patients have PFS. desert meaningful in rate

observe chemotherapy alone. median to receiving of we in compared However, for for an OS XX.X months patients trilaciclib, receiving did months improvement XX.X patients

curves which in excuse overall did of robust is months, hazard separate this time. negative result PD-LX Leading X.XX, Kaplan-Meier interestingly, accelerate XX not but me. More to for patients continued very to separation tumors, until survival a with over a then these about ratio

we present evaluate the particular in can patient outcomes measures and we these will whether most that improve will interested trilaciclib overall are while in survival for settings. watch So months, to of early the following meaningfully these coming response patients in PFS

pivotal TNBC that overall and same reach we bladder expect to X we mentioned, interim will trial. the quarter anticipate studies we This ADC survival endpoints I line see the analysis of approximately OS for the As XXXX. in the for the Phase is first time currently first

year, early be So an for will exciting us. certainly time next

the I review will John, turn financial that, a With call over results. for to the of

John Umstead

Raj Thanks, and good morning, everyone.

today morning’s first after mentioned market which Will, quarter in this closed. are we XX-Q, will full expect the XXXX press available about and be in from release the financial As results

for is from revenue Simcere. of reimbursements million, million XXXX and current supply comprised first quarter Our COSELA manufacturing revenue The licensed revenue revenue revenue trial net clinical $XX.X services $X.X license million. Simcere, $XX.X the and and from royalty and of quarter to Simcere from EQRx related total was with of of the

of period goods same revenue $X.X net the compared was XXXX, X-months XXXX, the same was for Cost product of million, including $X.X to million $X.X for million, For $XXX,XXX XX, March period revenue. in in total sold XXXX. the ended

costs. for the were R&D trial XXXX reduce due expenses to compared to $XX.X quarter period-over-period of quarter of Our research in was and The first clinical development the decrease $XX.X first for million million, primarily expenses XXXX.

Our first first of commercialization to million, the the decreases was XXXX fees. two Comparing due primarily selling activities, $XX.X for personnel quarter of in expenses $XX.X periods, professional administrative general were expenses for and SG&A XXXX. to the the compared quarter and million decrease in costs

mentioned XXXX our quarter As see XX% that last on operating we the severance first due associated the while expenses We to XX%, of to than PRESERVE X. see didn’t in start in the and year. quarter, of be current half XXXX. impact it of with down costs the second expect to call, we lower winding the will But occurring with savings most in we to the the

million as cash, liquid position, cash December cash equivalents of and million, XXXX. $XXX.X compared $XXX.X XX, quarter our first the to of securities Regarding we with ended

us cash announced without mentioned position, we sheet our even TNBC trial. by milestones Phase equity quarter that to additional X issuing as Jack the of morning royalties pending strengthened While and future which as and data start, positive on our total. The million this $XX the topic monetizing the in Simcere are further we ongoing at balance the from up brings of pivotal million $XX additional $XX our from million current

filing would All on aspects in million the an data in on and million in and GX cost participation $XX approval clinical an receive collaboration China. sharing including on Specifically, trilaciclib. additional sharing $X global other an remain of NDA additional place in trials and strategic China, of

runway cash into further XXXX. able of result a to our transaction, are extend even As now we this

readouts of China geography. Raj earlier. Greater our a that trials, the And was reminder, the discussed only Beyond clinical partner as

retain the the commercialize As such, trilaciclib rest and we rise develop to throughout the of world.

runway due guidance impact to product gross conservatively XXXX. the the reiterated to wastage and XXXX Finally, a be We $XX million. low and provision percentage to guidance million the between for expense XXXX the bill. our for net we our potential regarding to primarily cash range of Today, estimate revenue infrastructure in net $XX of revenue mid-XXs, XXXX of

guidance, earlier. yearend $XX of result marketable taking the and cash a into cash, we of As anticipate $XX the million impact our balance sincere approximately securities to and million of account expense monetization, discussed revenue cash before equivalents a I

With back closing Jack that, call comments. some the I’ll turn over for

Jack Bailey

you, inspiration living Thank every drive Will. day. us Andrew with thank as I the toward people And Raj, cancer for always, your goals John, and want to to our

remain Now, the and confident as COSELA are driving lung you potential cancer heard making from of Andrew, and we results. progress in good in real

During grew net March XX for the prior sales accounts. the XX% and record on first brought quarter, onboard accounts, Vials we we our and month Vial product line new new quarter, Volume both best by XX%, over by was

customers Volumes compared ordered quarter had contracted XXX depth, than fourth that more we our in to XX during in XX Regarding organizations the quarter, and Vials increased the XX%.

have we XXXX. of million million this net COSELA guidance for Given reiterated $XX and sales our between $XX

heard including X bladder our Beyond tumor quarter the line, the later followed trials, TNBC trial X from you by from And by expect pivotal analysis the Phase Phase now quarter sales additional mid-year. trial occur first to in expect Raj, of Phase both from cancer will status OS results XXXX. data this the additional X of we the we for present interim ongoing TNBC as PD-LX

Finally, readouts the runway added capital beyond trial to in expected extend early clinical even additional further near-term important XXXX. we cash our have

our sector next we product have novel months, less our that and in positivity should in is us also pipeline assuming in few companies pivotal internal late-stage forecasts data cash years. hit but improved with expected few very the drive important the growing, of an XX one that are flow We not which have to only than

morning. you your this Thank time for

quarter opportunities on in have the throughout variety calls we second And will We the the trials upcoming of XXXX again X communicate speak in of August. to from Phase format will a this results our year.

call, turn With Q&A. how ask over question? please that, our close Operator, the remind listeners would I’ll it to to a you

Operator

& Gil of Company. you. Blum Thank be from will Our [Operator first Needham ahead, Gil. Go question Instructions]

Gil Blum

everyone and morning, here. continued on execution Good congratulations

because just if I since default. on one know hazard meaning how well, don’t that. expected I a missed EMR this I maybe many centers heard adjustments as So went very

Jack Bailey

Gil. thanks, Yes,

at standard about in roughly So, default organization continue of one to to this of care is their of the with the COSELA to organizations selection to around can work as our how And executional strategies they educate we X,XXX for have customers EMR. have point, do that them themselves.

So growth we’re offers that that excited as about potential we the forward. and see great moving strategy a

Gil Blum

are the important it’s steps? more Raj And carefully here, Thank a can poster. mean, I in for you for for readouts you’ve looking so a the what at this could data maybe what [indiscernible] the OS, interim be we learn guiding and And you been we on XX clarification. interesting, May couple but at further

Raj Malik

Yes. Gil. Hey,

present that the So the data. safety data will will be updated

or PFS got well important got today, that effect And T-cells. that point cold I but That or more some. the data, I on Sorry, believe the rate have generation as the is, response mentioned, the long-term through which as I reason as for data. have OS early something is and surveillance, just is memory immune really but we

So as – be data have present at response should and stage we will considered that we but rate the that well. immature this PFS

Gil Blum

curves similar you on assuming PFS here that the very the cancer positive that’s should kind some a be reflect it? possibility on in bladder OS, couldn’t of it and And there. will see you study and I data separation presenting of future mean, a topic,

Raj Malik

correct. is That That is correct.

Gil Blum

to the the more beginning of hearing end at look at next – I year. forward of Okay,

Thank first going you’re to like Sounds have busy pretty you. a quarter.

Jack Bailey

Yes.

Operator

from our White, will Wainwright. come And question Instructions] H.C. next [Operator Ed

Ed White

for Good question. morning, taking my thanks

I’m is if about cycles. drug be duration? on and that X.X of be that approved? you done cancer can be So also for X.X wondering number patients length there’s drugs time were anything that indication how breast patients quarter, mentioned holding that should thinking once just that in And then increase to roughly will triple last we is on negative the to if

Andrew Perry

Yes, the standard undergoing chemotherapy is for the cycles, XX-day four line question. thanks so patients cycle. Yes, for first

So of it’s duration therapy. XX-day

it to in or – X.X hovers we it X So, quarters. let’s X.X on between last average, of average always see really say about couple the and on as before

who have extending product. that often the a experience bringing closer sometimes new with to And point or cycle new that apply longer a a or accounts, onboard of has to we in first reached existing the I they has patient care that four, held terms is growing standards that have actually of it’s think In no third second the already patient. that account discovered remember where

So we I X as accounts bring and that X.X. continue to would new will onboard hover between expect number the

topotecan But In the terms smaller and that’s indefinitely. population obviously, do can of us. patient regimen extend duration, go extended their further for is on because different patients so they a

into that again, obviously then longer cancer, there is we cycles treatment XX triple-negative progression In would circumstance, of as potential breast a could a And moving the cancer. duration breast it therapy. triple and XX to be expect the negative

So presence market duration of very be out that’s larger build exciting therapy. to and a a proposition able to more

Ed White

Thanks, mentioned you question, in that the first for gross year the was to it mid-XXs. housekeeping the net to Great. be a What And quarter? Andrew. just in expected is

John Umstead

first just It quarter. under XX% for was the

Ed White

$XX expect the when U.S. to us Okay. you million million just last any then And Can with you those agency timing $XX receive question the the Chinese then on with nothing regulatory my the the familiar Simcere left, as two regarding the of approval, and guidance with give $X payments? on is million the payments

Jack Bailey

around is delay Jack. U.S. use the This quarter would somewhere from Yes. I one

to a all about it, to and two are delay three months it data talking us. get you usually from So, quarter requisite submit months the but takes able be to only

you the see would and expect our filing quarter market. adding a you that can be in Chinese safe, when date, So,

Ed White

questions. Great. Thanks taking Jack. my Thanks for

Jack Bailey

Thanks Ed.

Operator

stand-by Thank question. you. next up while we our Please bring

James. Our next Raymond from Dane come question will of Leone

Dane Leone

trajectory. Thank for maybe you for Two and commercial me, questions for the congrats the on taking first Jack. with execution COSELA one questions

quarter this actually label end that the account. current had to arm, in advantage maybe on EBIT an becomes but One, EB-XXX different PFS of secondly, or if care on if and R&D that twofold. current But What positive. COSELA bladder could the be asked theoretically OpEx of breakeven the advantage point year you seems of trajectory regimen. to with maybe myeloprotection file studies reading for take of of kind and commercial with You into the Jack, equivalent of are the SG&A today, about for strategically primary is something outcomes. you I that the here, a kind you again, current The of trajectory what commercial burn. I then that like you positive to you the endpoint effects, outcome terms PFS, bulk if some expansion reason debatable, the in the of X the second are that much thinking happens or primary within was hit ongoing and that that. hint be? my the OS on label the But have How margin this protective we the reality from study assume a Even the because where or standard rationalized out that’s then discussed could be would with an of cancer, on COSELA have obviously what versus I talking secondly, that to think you guess, be study is the question before going frontline for theoretically PRESERVE you Raj likely And PFS about study?

you chemo the on could file care the mile what the under maybe if effect just have versus see a you. complexity to and to then protective of move weight, of smart manage of shift frontline a standard now Thank care? in So, frontline

Jack Bailey

flip it to for then second I the one Yes. over Thanks Dane. the first tackle one. will Raj and

the years having we and in positive, of site. would the you burn, and sales we X profitability mentioned, reducing flow in have when of, at think taken of sort as look were, trajectory terms say actions our being I from our I cash

to sales obviously always tightly trajectory to it quarter, flip we as than manage else, the more But are Raj. but on So, as it look will expense largely going base will anything depend question, the or to possible. second on take our I give a over

Raj Malik

Yes.

study So, avelumab doing study on is, to you enhancing and looking evaluate are the how IO was combined PFS, trial. effect think is to mention just primary, Dane, this important PFS the trials rationale at the as the for point I said, to on

myelo, Regarding a with not of of think effects is recall points any TNBC. couple to I side containing jump being And have there, a this seen regimen. we myelo that

it’s So, that that unlikely the we will with we see think bladder regimen.

However, it We depends let’s just that on could have in of we TNBC. low set what based study data what see we course saw just the myelo would think with then likelihood what agency, the strength selected it’s depending in show benefit. discussions that. the a we on the But And to previously the data, shows. the of but on expectations

Dane Leone

Okay. Thank you.

Operator

while we stand-by question. up Please our you. bring Thank next

Our TD next from come will question Troy Cowen. Langford with

Troy Langford

Raj and quick quarter. Hi, just commercial have that. I have everyone. two the ones, all follow-up congrats this for one Thanks on one, and progress for taking We after then a questions

the all you your quickly hope like sales quarter, given you do expectations the to you COSELA, you And of just to XXXX for So, or the sales? inflect think course numbers the how year? in you just what else like think over do internal need trajectory the how COSELA hit for year to the full all order expect customer

Jack Bailey

Thanks. Yes.

see years may So, the on ongoing present through before, ahead the basis. that do so little said a have choppy, some we and be growth downs month-to-month ups as guidance. We can month-to-month we a bit

to and market with So, obviously for new the accounts for level was that And accounts. in there based number I we product. new a way demand is there March on a we seen, new is what a the testament added the a of good of it’s have think good enter that

like COSELA to have I going growth need we but extensive to to at tumor we in think stage we sure So, it account inflate growth, we cell provider fuel systematize relatively to terms is right rare feel making can and a be forward. levels. got strategy needs complicated executional because what that building types. small physician of And the too to the still do It’s is champions don’t continue it

of system, able a we optimal help time reminders these billing to it’s sure patients. of mind based top in then very that helps and the to product to placement, more those at certainly uptake in we deeply the the allows [indiscernible] that systemize and an generate will targets. those have more which see level. If right, the us right at and similar more organizational things opportunity give got make And leading contracts, overall will we to the thing, EMR So, COSELA have to is us of organizations, be market, ideally of really the the which course, was ultimately

Troy Langford

more Okay. to one Trodelvy, confident pivotal in in that – order then to for just with decision X from I Phase move in Great. of just terms a Raj. data What a And the study? feel the remind can clinical see you you combination in to guess us forward what would study need

Raj Malik

Yes.

have quarter Troy, the will I really we that first as year. be of will the it’s mentioned, So, which data be looking survival at, overall next

San, breast, patients well for population checkpoints at more as example, many what compared study. who have to to data, be patient our the is what compared is, prior I that we looking have For will

in as rate early the most So, evaluating are and as but survival year that PFS the that the data early next looking the it’s the interested quarter. response in context we first well at really, overall safety,

Troy Langford

guys. Thanks Great.

Operator

Thank you. bring question. Please we next stand-by our up while

next will with Our be question Anupam JPMorgan. Rama from

Unidentified Analyst

regards flow Simcere the the granularity for or is on cash guys. Hi, Can on agreement? This in more you provide Anupam. cash to Priyanka

John Umstead

This XXXX into Raj mentioned will first the us in allow year. get cash with that is continue Priyanka, Yes, Yes. on the so continuing the to through to and of $XX the thanks. inflow mentioned, trial this John. million we that half readouts of

Unidentified Analyst

it. Thanks. Got

Operator

one our you. we Thank while Please next bring moment question. up wait

David. will ahead, Our Nierengarten be question David Go Wedbush next Securities. from with

David Nierengarten

Trodelvy the my if to question. that triple about I just I think mean is the and ADC is versus year? points with for follow-up read-through, in important confidence chemo cancer. different we the for the the going people toxins thinking would involved with combo QX to next upcoming there Thanks any back can taking chemo the help from a read-through versus any about, just backbone give other or had from next extract year there backbone data data is QX, and negative breast the in to that in

Jack Bailey

understand, knew TNBC him ADC to understanding the specifically study the just David, study am for I to just asked or question. and through I read your I So,

David Nierengarten

partners a It’s to is different different I it’s of different Yes. mechanism mechanism maybe from Can to in are are – about the chemo trials but look that isolation two study a like that at mean with that partner, Thanks. a another until here think say has, different But read action just each question have a we trying like, from other? there wasting more we actions. study a of through we anything like, to it, well, brain cells basic drugs we with sorry

Jack Bailey

question. a good That’s Yes,

strongest which I very gem-carbo, the to effect. think TNBC the right, same strong X the X is Phase saw the we Phase data, is read-through the so doublet where and

an with the we terms ADC point, information, of the for may X So, expect TNBC it’s Phase X. obviously. the of that strongest X evidence Phase trial think trial, in gem-carbo trial that in will your additional, piece Phase important the really be provides I But TNBC what

David Nierengarten

Okay.

you, to guys. wanted Thank that. on triple Just check

Operator

Thank you. next next Please with Pohlman stand-by from will question question. BTIG. Go ahead. our our for Kaveri And come

Unidentified Analyst

covering at Christian today. we is Hey. questions be will are here asking the Good morning [ph] everyone. BTIG. I This

the theories question have interacting chemo is, some I way. drug negative with a in first So, your on you assume

future? finding any back that models in to preclinical your the combinations you be might If retrospect are where predict kind go of there useful this in data, for

Raj Malik

So, this Raj. is

a cell are refer here we where not in small in because terms colorectal So, in certainly to showed way, when you referring I negative we and your to the an of TNBC, have Just survival, seen you question. that so specifically study improvement understand

Unidentified Analyst

Yes. Colorectal cancer.

Raj Malik

Yes.

we are currently. there So, doing a investigations number actually of

unexpected potentially them. an yes, we so with of one our we will that obviously when there certainly And those was have interaction is, in resulted that’s hypotheses data release But T-cell. X-FU,

Unidentified Analyst

I that CRC preclinical way the how first And regimen chemo? that or giving chemo saw a is was have best Okay. is later clear you versus using suggesting with chemo been before models. trilaciclib wondering your inhibitors anything That which brings see of little X-FU, there that effect with of my question, the me with where is an to some CDKX/X benefit if next kind chemo. antagonistic suggests to after studies like that the actually And

Raj Malik

Yes.

specifically of preclinical benefits. had showed combination, for work, data trila, with which lots in checkpoint myeloprotection And it a we was was we showing I of course, X-FU efficacy. had in few mean that an a So, done improvement inhibitor with actually

that suggest was So, would see that what therapies again, And also as colorectal. with – we we in data certainly there to saw work was pre-clinically no we no did there well. chemo other

this to We work different expanding understand given better our it. are with now chemotherapies looking data at definitely

Unidentified Analyst

Okay. Thank you that so much for providing clarity.

Operator

CEO I back turn you your questions. now it to will for for Thank Jack everyone remarks. Bailey, closing

Jack Bailey

operator. you, Thank

As always, Thank call us keeping everyone as the we joining forward for look you progress. to on updated we today.

We again will speak soon.

Operator

call. Thank now you today’s for your This concludes everybody participation. conference

disconnect. may You

G1 Therapeutics (GTHX) 3 May 232023 Q1 Earnings call transcript